Combinations Alliance EOI Calls - Biothera

We are delighted to announce that an additional company has joined the Combinations Alliance. Biothera are the latest company to offer their novel agent to the ECMC Network through this initiative and we look forward to a successful collaboration with them.

The agent on offer is Imprime PGG, a novel Innate Immune Modulator, currently in Phase 3 trial in combination with cetuximab for CRC (other Phase I/II combination studies also underway).

Potential areas of scientific interest are:

1. Novel combinations with approved or advanced stage (phase 3 results available) complement -activating antibodies, in particular in areas of high unmet medical need (hematology or oncology)

• Clinical safety and preliminary efficacy (e.g. combination with ofatumumab in CLL)

2. Translational research studies elucidating evidence of biological impact in human

• Clinical and correlative endpoints (e.g. pre-surgical window of opportunity or neo-adjuvant study in breast cancer)

3. Novel combinations in immune modulation

• Preclinical or clinical research (e.g. PD-L1)

Biothera presented data on Imprime PGG via webinar, which you can listen to here.

Please also refer to the non-confidential data package for further details.

Studies must fit the remit of the Combinations Alliance (dose escalation + small proof of concept expansion arm(s) with a strong translational element)

If your second novel agent of choice is not currently available within the Combinations Alliance portfolio, we will contact companies of interest on your behalf.

We also welcome EOI proposals that require additional preclinical work. These proposals will be discussed with the company with opportunities for direct funding or application to the NAC preclinical funding stream.

EOIs that are clinic ready, require access to an additional compound for the proposed combination or additional preclinical evidence are invited to be submitted on the EOI template (see also accompanying guidelines) to the Combinations Alliance mailbox by the 16th February 2015. We hope this will be of interest to the ECMC Network and look forward to receiving your EOIs.

Summary of key dates